A.I. Trading System Helps Some Traders Pocket $1,100 per DAY!

What if I told you 60 seconds a day could completely change your life?

This AI-powered trading system finds high-probability option trades in less than 60 seconds a day

Click HERE to access this powerful AI Trading System

Mark C. Throdahl net worth and biography

Mark Throdahl Biography and Net Worth

CEO of OrthoPediatrics

As of June 2021, Mark will step aside as Chief Executive Officer, a position he has held for the past decade, and will become Executive Chairman of the Board. He brings a wealth of knowledge to the Company through his successful experience as a medical technology executive working in both domestic and international settings. Prior to joining OrthoPediatrics, he served as Group President of Zimmer and Chief Executive of Consort Medical plc in London. During a 13-year career at Becton Dickinson & Co., he served as Senior Vice President, President of the Drug Delivery Sector, and President of Nippon Becton Dickinson in Tokyo. He began his career at Mallinckrodt Group. Mark is a graduate of Princeton University and has an MBA from Harvard University.

What is Mark C. Throdahl's net worth?: The estimated net worth of Mark C. Throdahl is at least $3.12 million as of March 11th, 2024. Mr. Throdahl owns 137,857 shares of OrthoPediatrics stock worth more than $3,118,325 as of December 24th. This net worth evaluation does not reflect any other investments that Mr. Throdahl may own. Learn More about Mark C. Throdahl's net worth.
How old is Mark C. Throdahl?: Mr. Throdahl is currently 73 years old. There are 6 older executives and no younger executives at OrthoPediatrics. Learn More on Mark C. Throdahl's age.
How do I contact Mark C. Throdahl?: The corporate mailing address for Mr. Throdahl and other OrthoPediatrics executives is 2850 Frontier Drive, Warsaw IN, 46582. OrthoPediatrics can also be reached via phone at (574) 268-6379 and via email at [email protected]. Learn More on Mark C. Throdahl's contact information.
Has Mark C. Throdahl been buying or selling shares of OrthoPediatrics?: Mark C. Throdahl has not been actively trading shares of OrthoPediatrics during the past quarter. Most recently, Mark C. Throdahl sold 2,433 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $27.59, for a transaction totalling $67,126.47. Following the completion of the sale, the director now directly owns 137,857 shares of the company's stock, valued at $3,803,474.63. Learn More on Mark C. Throdahl's trading history.
Who are OrthoPediatrics' active insiders?: OrthoPediatrics' insider roster includes Bernei Berry, III (Director), Stephen Burns (Director), Fred Hite (CFO), Marie Infante (Director), Gregory Odle (EVP), Jennifer Pritzker (Major Shareholder), Terry Schlotterback (Director), and Mark Throdahl (CEO). Learn More on OrthoPediatrics' active insiders.
Are insiders buying or selling shares of OrthoPediatrics?: In the last twelve months, insiders at the sold shares 7 times. They sold a total of 27,253 shares worth more than $770,374.68. The most recent insider tranaction occured on August, 21st when General Counsel Daniel J Gerritzen sold 10,000 shares worth more than $293,000.00. Insiders at OrthoPediatrics own 31.8% of the company. Learn More about insider trades at OrthoPediatrics.
Information on this page was last updated on 8/21/2024.

Mark C. Throdahl Insider Trading History at OrthoPediatrics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	2,433	$27.59	$67,126.47	137,857
3/6/2023	Sell	4,515	$43.83	$197,892.45	128,024
3/2/2022	Sell	5,961	$58.60	$349,314.60
3/1/2021	Sell	5,097	$55.88	$284,820.36	146,460
2/4/2021	Sell	7,349	$50.18	$368,772.82	164,208
6/25/2020	Sell	13,389	$42.88	$574,120.32
5/20/2020	Sell	1,876	$46.56	$87,346.56	155,616
12/13/2019	Sell	10,000	$34.31	$343,100.00

Mark C. Throdahl Buying and Selling Activity at OrthoPediatrics

OrthoPediatrics Company Overview

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Today's Range

Now: $22.62

$21.90

$22.77

50 Day Range

MA: $25.19

$21.92

$30.95

2 Week Range

Now: $22.62

$21.02

$36.23

Volume

255,831 shs

Average Volume

176,447 shs

Market Capitalization

$547.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14